| Description |
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP)[1].
|
| Related Catalog |
|
| In Vitro |
XmAb 5592 (0-1000 ng/mL) 增强对多发性骨髓瘤 (MM) 细胞的抗体依赖细胞细胞毒性 (ADCC) 和抗体依赖细胞吞噬作用 (ADCP)。与 IgG1 类似物相比，XmAb 5592 在 5-27 ng/mL 范围内显著增加所有细胞系 ADCC，还可增强巨噬细胞的抗体依赖性细胞吞噬作用 (ADCP)[1]。 XmAb 5592 (0-10000 ng/mL) 通过脱颗粒 NK 细胞诱导强烈的 MM 细胞裂解，即使存在骨髓基质细胞 (BMSCs)[1]。
|
| In Vivo |
XmAb 5592 (0.3-9 mg/kg；i.p.；每周 2 次，每次 7 剂；RPMI8226 荷瘤 SCID 小鼠) 通过 FcγR 依赖机制抑制携带人 MM 异种移植物的小鼠的肿瘤生长[1]。 Animal Model: SCID mice with palpable RPMI8226 tumors[1] Dosage: 0.3, 3 and 9 mg/kg Administration: Intraperitoneal injection; twice weekly for 7 doses Result: Inhibited growth of established myeloma tumors in vivo and eradicates tumors in mice.
|
| References |
[1]. Tai YT, et, al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 1;119(9):2074-82.
|
